- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06410248
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate the recommended phase 2 dose (RP2D) for triapine (3-AP) in combination with temozolomide (TMZ).
SECONDARY OBJECTIVES:
I. To evaluate the safety profile of triapine in combination with temozolomide (TMZ).
II. To evaluate progression-free survival (PFS). III. To evaluate overall survival (OS). IV. To evaluate the overall response rate (ORR) per Response Assessment in Neuro-Oncology (RANO) criteria.
EXPLORATORY OBJECTIVES:
I. To investigate the distribution of triapine within tumor and peritumoral areas post oral administration and correlation with serum levels.
II. To investigate the potential interaction of drug absorption when administrating oral triapine and temozolomide together by measuring plasma levels triapine and temozolomide post administration.
III. To evaluate oral triapine plasma pharmacokinetics and corresponding methemoglobin level by venous blood gas proportion.
IV. To evaluate the quality of life per Functional Assessment of Cancer Therapy-Brain (FACT-Br) for patients treated with triapine and temozolomide.
OUTLINE: This is a dose-escalation study of triapine in combination with temozolomide. Patients with recurrent glioblastoma not planning to undergo surgery are assigned to group 1 or group 2. Patients with recurrent glioblastoma planning to undergo surgery are assigned to group 3.
GROUPS 1 AND 2: Patients receive temozolomide orally (PO) once daily (QD) and triapine PO QD on days 1-5 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo magnetic resonance imaging (MRI) at screening and on study and undergo collection of blood samples on study.
GROUP 3: Patients receive triapine PO QD for 5 days prior to surgical resection. After surgical resection, patients receive temozolomide PO QD and triapine PO QD on days 1-5 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI at screening and on study and undergo collection of blood samples on study.
After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 24 months.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Study Coordinator
- Phone Number: 3126951301
- Email: cancer@northwestern.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
Contact:
- Karan Dixit
- Phone Number: 312-503-1818
- Email: karan.dixit@northwetstern.edu
-
Principal Investigator:
- Karan Dixit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histologically confirmed World Health Organization (WHO) grade 2-4 glioma, isocitrate dehydrogenase (IDH) wild type (WT) (by immunohistochemistry [IHC] R132H negative [neg] or sequencing). Astrocytoma with molecular features of glioblastoma (GBM). Confirmed diagnosis via molecular testing
Patients must have an established diagnosis of recurrent glioblastoma and:
- Group 1 and 2: recurrent glioblastoma
- Group 3: Surgically amenable recurrent glioblastoma
- Patients must have stable or decreasing dose of corticosteroids equivalent to ≤ 6 mg dexamethasone, for ≥ 7 days prior to registration
Patients with disease that has progressed after a standard or investigational first-line therapy (e.g. radiotherapy [RT], RT plus temozolomide) with or without tumor treating fields therapy (TTFields)
- Note: Patients who have received fractionated first-line radiation therapy and no prior chemotherapy (e.g. as common practice for MGMT unmethylated tumors), or who have participated in an investigational protocol substituting TMZ for a novel agent are eligible
- Patients must be able to undergo contrast-enhanced magnetic resonance imaging (MRI)
- Patients must be age ≥ 18 years
- Patients must exhibit a Karnofsky performance status ≥ 70
- Leukocytes (white blood cells [WBC]) ≥ 3,000/mcL
- Absolute neutrophil count (ANC) ≥ 1,500/mcL
- Hemoglobin (Hgb) ≥ 8 g/dL (transfusion may be used for eligibility outside of 7 days)
- Platelets (PLT) ≥ 100,000/mcL (transfusion or growth factor may be used for eligibility outside of 7 days)
- Total bilirubin ≤ 2 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 x institutional ULN
- Creatinine ≤ 1.5 x institutional ULN
- International normalized ratio (INR) ≤ 1.5 x ULN
- Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.5 x ULN
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
Patients of child-bearing potential (POCBP) must agree to use two forms of adequate contraception (hormonal or barrier method of birth control, abstinence) from time of informed consent and for the duration of study participation. Patients who can impregnate their partners must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) from time of informed consent and for the duration of study participation
- Should a patient become pregnant or suspect they are pregnant while they or their partner is participating in this study, they should inform their treating physician immediately.
- Note: At the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)
Note: A POCBP is any person with an egg-producing reproductive tract (regardless of gender, sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy
Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months) (in patients > 45 years of age in the absence of other biological or physiological causes)
- Potential POCBP who may be menopausal and are < 55 years of age must have a serum follicle-stimulating hormone (FSH) level > 40 mIU/mL to confirm menopause
- Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff
Patient must be willing and able to comply with the protocol for the duration of the study and provide written, signed, and dated informed consent prior to study registration.
- NOTE: No study-specific screening procedures may be performed until written consent has been obtained
- Patients must have the ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
Patients who have a prior or concurrent malignancy that may interfere with study treatment or safety
- NOTE: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible, per principal investigator (PI) discretion
Patients who are receiving any other investigational agents.
- Exceptions: COVID-19 vaccine and treatment is allowed, per PI's discretion
Patient's interval since last cytotoxic therapy ≥ 1 cycle or ≥ 2 biological half-lives, i.e.
- ≥ 28 days since start of last cycle of temozolomide (cycle length-28 days)
- ≥ 42 days since start of last cycle of lomustine or other nitrosourea (cycle length-42 days)
- ≥ 21 days since start of last cycle of a small molecule targeted agent (cycle length-21 days)
- ≥ 42 days from last bevacizumab infusion (cycle length-42 days)
- Patients who have a history of allergic reactions attributed to compounds of similar chemical composition to temozolomide or triapine
- Patients with spinal cord and diffuse leptomeningeal dissemination
- Patients with a history of G6PD deficiency or other congenital or autoimmune hemolytic disorders. All participants will be screened for G6PD levels prior to registration
Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following:
- Have uncontrolled epilepsy
- Have an uncontrolled intercurrent illness
- Are pregnant or nursing
- Concurrent malignancy (outside of glioblastoma) that requires tumor directed treatment
- Known concurrent shingles, herpes, cytomegalovirus (CMV) infection
- Known concurrent opportunistic fungal infection
- Known immunodeficiency that could lead to opportunistic infections
- Psychiatric illness/social situations that would limit compliance with study requirements
- Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints
- Patients who are pregnant or nursing. Pregnant patients are excluded from this study because temozolomide is an alkylating agent with potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide, breastfeeding should be discontinued if the mother is treated with temozolomide
- Patients who are unable to swallow oral medication or have problems/diseases that affect absorption or oral medication
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV). If patient does not have a known history testing will not be conducted
- Note: Temozolomide is an immunosuppressive agent. Patients with a known history of HIV, HBV, and HCV, and unexplained opportunistic infections are not eligible due to safety reasons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 3 (triapine, surgical resection, temozolomide)
Patients receive triapine PO QD for 5 days prior to surgical resection.
After surgical resection, patients receive temozolomide PO QD and triapine PO QD on days 1-5 of each cycle.
Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo MRI at screening and on study and undergo collection of blood samples on study.
|
Ancillary studies
Undergo collection of blood samples
Other Names:
Undergo MRI
Other Names:
Given PO
Other Names:
Undergo surgical resection
Other Names:
Given PO
Other Names:
|
Experimental: Groups 1 and 2 (temozolomide, triapine)
Patients receive temozolomide PO QD and triapine PO QD on days 1-5 of each cycle.
Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo MRI at screening and on study and undergo collection of blood samples on study.
|
Ancillary studies
Undergo collection of blood samples
Other Names:
Undergo MRI
Other Names:
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended phase 2 dose for triapine in combination with temozolomide
Time Frame: At the end of Cycle 1 (each cycle is 28 days) + 7 days (up to cycle 2 day 7)
|
The recommended phase 2 dose will be based on treatment-emergent and drug-related toxicity.
Dose limiting toxicities and adverse events (AEs) will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0.
|
At the end of Cycle 1 (each cycle is 28 days) + 7 days (up to cycle 2 day 7)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of AEs and serious AEs
Time Frame: Up to 30 days after last administration of study drug
|
Will evaluate the occurrence of toxicity (AEs and serious AEs) and the number of patients who discontinue treatment due to toxicity.
Toxicity will be assessed by CTCAE v. 5.0.
Adverse events will be sorted (by type, severity [grade], timing, and attribution to triapine), collected, and reported according to CTCAE v5.0.
|
Up to 30 days after last administration of study drug
|
Progression free survival (PFS)
Time Frame: From baseline until the patient experiences disease progression, initiates subsequent anti-cancer therapy, completes study participation, or experiences death from any cause, assessed at 6, 12, and 24 months
|
Progression will be determined by clinical progression or by radiographic imaging as assessed by Response Assessment in Neuro-Oncology (RANO) criteria.
The median and corresponding 95% confidence interval will also be estimated.
|
From baseline until the patient experiences disease progression, initiates subsequent anti-cancer therapy, completes study participation, or experiences death from any cause, assessed at 6, 12, and 24 months
|
Overall survival
Time Frame: From time of diagnosis until the patient initiates subsequent anti-cancer therapy, completes study participation, or experiences death from any cause, assessed at 6, 12, and 24 months
|
Will be described by Kaplan-Meier curve.
The median and corresponding 95% confidence interval will also be estimated.
|
From time of diagnosis until the patient initiates subsequent anti-cancer therapy, completes study participation, or experiences death from any cause, assessed at 6, 12, and 24 months
|
Overall response rate (ORR)
Time Frame: From baseline until the response has been confirmed, the patient experiences disease progression, the patient initiates, subsequent anti-cancer therapy, or the patient completes study participation, assessed up to 24 months
|
ORR will be assessed by RANO criteria.
To determine the ORR, this endpoint will calculate the proportion of treated patients who experience an overall response (complete response [CR] or partial response [PR] per RANO criteria).
The date of first response for either CR or PR will be used for the calculation of ORR.
Will be estimated using the expansion cohort, along with its 95% confidence interval.
|
From baseline until the response has been confirmed, the patient experiences disease progression, the patient initiates, subsequent anti-cancer therapy, or the patient completes study participation, assessed up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Karan Dixit, MD, Northwestern University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Astrocytoma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Recurrence
- Glioma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
Other Study ID Numbers
- NU 23C05 (Other Identifier: Northwestern University)
- P30CA060553 (U.S. NIH Grant/Contract)
- NCI-2024-02351 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- STU00220426
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent WHO Grade 2 Glioma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 GliomaUnited States, Canada
-
Susan ChangGE Healthcare; Sigma-Aldrich; Phillips-MedisizeRecruitingRecurrent WHO Grade III Glioma | WHO Grade III Glioma | WHO Grade II Glioma | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent WHO Grade 2 Glioma | Recurrent Glioblastoma, IDH-Wildtype | Recurrent WHO Grade 3 GliomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingGlioblastoma | WHO Grade 3 Glioma | Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Glioma | Recurrent Cholangiocarcinoma | WHO Grade 2 GliomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II GliomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); BeiGeneCompletedRecurrent Glioblastoma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | IDH1 Mutation | IDH2 MutationUnited States
-
Frank LiebermanUniversity of MinnesotaCompletedHigh Risk WHO Grade II Glioma | Recurrent/Post-Chemotherapy WHO Grade II GliomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Recurrent Gliosarcoma | Recurrent Anaplastic Astrocytoma | Recurrent Anaplastic Oligoastrocytoma | Recurrent Anaplastic OligodendrogliomaUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAdvanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting